Hematologic Malignancies Program
About Hematologic Malignancies Program
Since lymphoma is a cancer of the immune system, a major scientific goal of the Hematologic Malignancies Program is to use knowledge gained from immunology to understand and treat lymphoid malignancies. This goal is being accomplished by gaining better understanding of the biology underlying lymphoid and myeloid neoplasms and applying this knowledge to improve the diagnosis and treatment of these disorders.
- Discover the Genetic and Cellular Origins of Lymphomas and Leukemias
- Develop Novel Methods of Diagnosis and Biomarker Monitoring of these Diseases
- Develop New Therapies
Hematologic Malignancies Clinical Trials
Study Evaluating the Safety of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid LeukemiaStanford is currently accepting patients for this trial.
Stanford is currently accepting patients for this trial.
Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)Stanford is currently accepting patients for this trial.
Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell LymphomaStanford is currently accepting patients for this trial.